Vitamin K2 MK-7 is best known for directing calcium to the right places in your body: into your bones and away from your arteries. It does this by activating two proteins that most people have never heard of but that play a central role in bone strength and cardiovascular health. Beyond those core functions, newer research points to potential benefits for blood sugar control and even brain health.
How MK-7 Works in Your Body
Vitamin K2 MK-7 acts as a helper molecule for an enzyme that switches on two key proteins. The first is osteocalcin, a protein made by your bone cells. In its inactive form, osteocalcin can’t do much. Once MK-7 activates it, osteocalcin gains the ability to bind calcium ions and ferry them into bone tissue, where they’re needed for mineralization and strength.
The second protein is called Matrix Gla Protein, or MGP. When MK-7 activates MGP, it becomes a powerful inhibitor of calcium buildup in soft tissues, particularly your blood vessel walls. Without enough vitamin K2, MGP stays inactive, and calcium that should be reinforcing your skeleton can instead accumulate in your arteries. This dual action, building bone while protecting blood vessels, is what makes MK-7 distinct from most other vitamins.
Why MK-7 Over Other Forms of Vitamin K
Vitamin K comes in several forms. K1 is found in leafy greens and is primarily used by your liver for blood clotting. K2 exists as multiple subtypes, with MK-4 and MK-7 being the most discussed. The key advantage of MK-7 is how long it stays active in your bloodstream.
In a direct comparison study in healthy women, MK-4 was undetectable in the blood at every time point measured after a single dose. MK-7, by contrast, reached peak blood levels about 6 hours after intake and remained detectable for up to 48 hours. That extended presence gives MK-7 more time to activate osteocalcin and MGP throughout your body. It’s the reason most K2 supplements on the market use the MK-7 form.
Bone Health: What the Evidence Shows
The connection between MK-7 and bone metabolism is well established at a biological level. MK-7 clearly activates osteocalcin. In a three-year clinical trial of postmenopausal women with early bone loss, daily MK-7 supplementation (375 micrograms, alongside calcium and vitamin D) reduced inactive osteocalcin by about 65% compared to virtually no change in the placebo group. That’s a strong signal that the vitamin was doing its biochemical job.
The catch: this same trial found no measurable difference in bone mineral density between the MK-7 group and the placebo group over three years. Bone density declined at a similar rate in both groups at the hip, femoral neck, and lumbar spine. Earlier results from the same study had shown improved bone microarchitecture at the one-year mark, but that advantage didn’t hold up over the full three years. So while MK-7 activates the right proteins, its ability to meaningfully slow bone loss on its own hasn’t been confirmed in rigorous trials. It likely works best as part of a broader approach that includes adequate calcium, vitamin D, and weight-bearing exercise.
Cardiovascular Protection
The cardiovascular case for MK-7 may actually be stronger than the bone case. Arterial calcification, the gradual buildup of calcium in blood vessel walls, is an early feature of atherosclerosis and a well-established predictor of heart disease. MGP is one of the body’s main defenses against this process, and it depends on vitamin K2 to function.
Some of the most compelling indirect evidence comes from people taking blood-thinning medications that block vitamin K recycling. These patients consistently show more aortic and heart valve calcification than people not on those drugs, essentially demonstrating what happens when vitamin K-dependent proteins can’t do their job. Observational studies in healthy older adults show the inverse: higher dietary intake of menaquinones (the K2 family) is associated with less coronary artery calcification.
In a one-year clinical trial of 243 people aged 40 to 70 who had markers of vitamin K insufficiency, 180 micrograms of MK-7 daily produced a significant decrease in arterial stiffness, measured by the speed at which pulse waves travel through arteries. Stiffer arteries force the heart to work harder and raise the risk of cardiovascular events, so this is a meaningful finding. A separate three-year trial using the same dose in healthy postmenopausal women also showed improvements in arterial elasticity.
Blood Sugar and Insulin Sensitivity
A large prospective study following over 38,000 people for 10 years found that higher dietary intake of vitamin K2 (but not K1) was strongly associated with a lower risk of developing type 2 diabetes. A randomized controlled trial tested this more directly: insulin-dependent diabetic patients who took 360 micrograms of MK-7 daily for 12 weeks saw significant improvements in fasting glucose, insulin levels, and a standard measure of insulin resistance called HOMA-IR. Their long-term blood sugar marker (HbA1c) also improved. This is still a relatively small area of research, but the early clinical results are notable.
Brain Health
Animal studies have found that MK-7 treatment reversed age-related cognitive decline in older rats, improved markers of inflammation in the brain, and reduced calcification of blood vessels that supply the brain. The proposed link is straightforward: if MK-7 protects arteries elsewhere in the body, it likely protects cerebral blood vessels too, and healthy blood flow to the brain is essential for cognitive function. Human trials in this area are still lacking, but the vascular mechanism is plausible and consistent with what MK-7 does in other tissues.
How Much You Need
There is no official Recommended Dietary Allowance specifically for vitamin K2. The NIH sets an Adequate Intake for total vitamin K (K1 and K2 combined) of 120 micrograms per day for adult men and 90 micrograms for adult women, but this was based primarily on K1 and blood clotting needs, not the broader functions of K2.
Clinical trials showing cardiovascular benefits have typically used 180 micrograms of MK-7 per day. Trials focused on bone or metabolic outcomes have used doses ranging from 180 to 375 micrograms daily. No upper intake limit has been established for vitamin K, and MK-7 has not shown toxicity in studies at these doses.
Food Sources
The richest dietary source of MK-7 by a wide margin is natto, a Japanese fermented soybean dish. Regular natto contains roughly 775 micrograms of MK-7 per 100 grams, which is several times the dose used in most clinical trials in a single serving. Fortified versions of natto can contain over 1,700 micrograms per 100 grams. Other fermented foods like certain aged cheeses contain smaller amounts of various K2 subtypes, but nothing comes close to natto for MK-7 specifically. For most people outside of Japan, supplements are the more practical route.
One Important Caution
If you take warfarin or similar blood-thinning medications that work by blocking vitamin K, MK-7 supplementation can interfere with your treatment. In animal studies, vitamin K2 completely reversed warfarin’s blood-thinning effect. This isn’t a subtle interaction. Vitamin K2 is specifically listed as contraindicated for patients on warfarin therapy. If you’re on any anticoagulant medication, talk to your prescribing doctor before adding MK-7 to your routine.